

Global Usher syndrome Drugs and Companies Pipeline Review H2 2017

Usher syndrome Therapeutic Pipeline Market Review, H2 2017

PUNE, INDIA, January 12, 2017 /EINPresswire.com/ -- <u>Usher Syndrome</u> -Pipeline Review, H2 2016

GET SAMPLE REPORT @ https://www.wiseguyreports.com/samplerequest/867090-usher-syndromepipeline-review-h2-2016

Summary

Usher syndrome is an inherited condition characterized by hearing impairment and progressive vision loss. The major



symptoms of Usher syndrome are hearing loss and an eye disorder called retinitis pigmentosa. Risk factors include retinal degeneration, prolonged, unprotected exposure to sunlight may accelerate vision loss. Treatment includes cochlear implants, hearing aids and Vitamin A supplementation.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Usher Syndrome – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Usher Syndrome (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Usher Syndrome (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Usher Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Discovery stages are 2 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Usher Syndrome (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Usher Syndrome (Genetic Disorders).

- The pipeline guide reviews pipeline therapeutics for Usher Syndrome (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Usher Syndrome (Genetic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Usher Syndrome (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Usher Syndrome (Genetic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Usher Syndrome (Genetic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Usher Syndrome (Genetic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.

Table of Content: Key Points Table of Contents 2 List of Tables 3 List of Figures 4 Introduction 5 Usher Syndrome Overview 6 **Therapeutics Development 7** Pipeline Products for Usher Syndrome - Overview 7 Pipeline Products for Usher Syndrome - Comparative Analysis 8 Usher Syndrome - Therapeutics under Development by Companies 9 Usher Syndrome - Therapeutics under Investigation by Universities/Institutes 10 Usher Syndrome - Pipeline Products Glance 11 **Clinical Stage Products 11** Early Stage Products 12 Usher Syndrome - Products under Development by Companies 13 Usher Syndrome - Products under Investigation by Universities/Institutes 14 Usher Syndrome - Companies Involved in Therapeutics Development 15 ...Continued

ACCESS REPORT @ <u>https://www.wiseguyreports.com/reports/867090-usher-syndrome-pipeline-review-h2-2016</u>

Get in touch: LinkedIn: <u>www.linkedin.com/company/4828928</u> Twitter: <u>https://twitter.com/WiseGuyReports</u> Facebook: <u>https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts</u>

Norah Trent wiseguyreports +1 646 845 9349 / +44 208 133 9349 email us here

This press release can be viewed online at: http://www.einpresswire.com

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2017 IPD Group, Inc. All Right Reserved.